
    
      This will be a Phase III, double blinded, multi-center, randomized, placebo-controlled study.
      Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days
      0 and 5. All treated subjects will be followed for efficacy and safety for 12 months.
      Subjects will visit the clinic on Days 0 and 5 for treatment, and then on Days 14, 42, 168,
      and 365. In between the clinic visits subjects will be contacted remotely on Days 84, 126,
      210, 252, 294, and 336. The subject's participation in the study will be for approximately 1
      year from Day 0.
    
  